小肠克罗恩病狭窄相关组织病理学评分系统:系统综述
本系统综述检索了截至2019年3月13日的Embase和MEDLINE,纳入所有在同一成人个体中分别评估炎症与纤维化的小肠克罗恩病组织学评分系统。分析发现各评分系统异质性大,均非基于现代评价指数开发原则构建,未经正式效度或信度检验,缺乏肌成纤维细胞肥大或增生的特异性指标。结论认为缺乏经过验证的纤维肌性狭窄组织病理学评分系统,其开发与验证是重要研究优先事项。
要点
- 现有克罗恩病狭窄组织病理学评分系统异质性大,均未经过正式效度或信度检验。
- 缺乏评估肌成纤维细胞肥大或增生的特异性组织病理学指标。
- 基于横断面影像评估狭窄克罗恩病的数据应谨慎解读,需开发并验证组织病理学指数。
核心结论
- 系统综述发现缺乏经过验证的评估纤维肌性狭窄的组织病理学评分系统。
- 现有评分系统均未按公认的评价指数开发方法构建,缺乏操作特性基本知识。
研究设计与样本
- 系统检索Embase和MEDLINE截至2019年3月13日的研究。
- 纳入使用组织学评分系统表征小肠克罗恩病并在同一成人个体中分别评估炎症与纤维化改变的研究。
主要发现
- 各评分系统间存在显著异质性,均非源自现代评价指数开发原则。
- 现有指数均未经过正式效度或信度检验。
- 尚无评估肌成纤维细胞肥大或增生这一重要病理成分的特异性指数。
临床怎么用
- 临床解读基于横断面影像评估狭窄克罗恩病的数据时应谨慎。
- 开发并验证组织病理学指数是重要的研究优先事项。
局限性
- 纳入评分系统异质性大,缺乏操作特性基本知识。
- 现有指数均未按公认方法开发,未经效度或信度检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Stenosis is a common complication of Crohn's disease (CD) that has no effective medical therapy. Development of antifibrotic agents will require testing in randomized controlled trials. Computed tomography enterography- and magnetic resonance enterography-based technologies might be used to measure outcomes in these trials. These approaches have been validated in studies of patients with symptomatic strictures who underwent imaging evaluations followed by resection with histopathologic grading of the intestinal tissue for inflammation and/or fibrosis (the reference standard). Imaging findings have correlated with findings from quantitative or semiquantitative histologic evaluation of the degree of fibromuscular stenosis and/or inflammation on the resection specimen. However, it is not clear whether histologic findings are an accurate reference standard. We performed a systematic review of all published histologic scoring systems used to assess stenosing CD. METHODS: We performed a comprehensive search of Embase and MEDLINE of studies through March 13, 2019, that used a histologic scoring system to characterize small bowel CD and assessed inflammatory and fibrotic alterations within the same adult individual. All scores fitting the criteria were included in our analysis, independent of the presence of stricturing disease, as long as inflammation and fibrosis were evaluated separately but in the same scoring system. RESULTS: We observed substantial heterogeneity among the scoring systems, which were not derived from modern principles for evaluative index development. None had undergone formal validity or reliability testing. None of the existing indices had been constructed according to accepted methods for the development of evaluative indices. Basic knowledge regarding their operating properties were lacking. Specific indices for evaluating the important pathologic component of myofibroblast hypertrophy or hyperplasia have not been proposed. CONCLUSIONS: In a systematic review of publications, we found a lack of validated histopathologic scoring systems for assessment of fibromuscular stenosis. Data that describe the operating properties of existing cross-sectional imaging techniques for stenosing CD should be questioned. Development and validation of a histopathology index is an important research priority.
引用
- Gordon IO, Bettenworth D, Bokemeyer A, et al. Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review. Gastroenterology. 2019. PMID: 31476299. doi:10.1053/j.gastro.2019.08.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。